肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展

随着免疫时代的到来,免疫治疗为乳腺癌提供了新的治疗方法。应用免疫检查点抑制剂(ICI)治疗乳腺癌已经在临床实践中取得了重大进展。但是,这种治疗药物只对少数患者有效,并且可能会导致免疫相关不良事件的发生,因此,必须通过使用相关的生物标志物来优化患者的治疗选择。最近,有研究证实肿瘤突变负荷(TMB)是一种可以预测乳腺癌免疫治疗疗效的新兴生物标记物。本文就TMB在乳腺癌患者免疫治疗疗效中的预测价值与应用现状等方面进行综述。

Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy

With the advent of the age of immunotherapy,breast cancer treatment has also opened a new treatment strategy.The application of immune checkpoint inhibitors(ICI)in the treatment of breast cancer has achieved remarkable success in clinical practice.However,because it is only effective for a small number of patients,immunotherapy may lead to the occurrence of immune-related adverse events.Therefore,the patient's treatment options must be optimized through the use of relevant biomarker.Recently,many studies have confirmed that tumor mutational burden(TMB)is an emerging biomarker that can predict the efficacy of breast cancer immunotherapy.The article reviews the predictive value and application status of TMB in immunotherapy for breast cancer patients.